J&J/Basilea’s Ceftobiprole NDA Edges Ahead
This article was originally published in The Pink Sheet Daily
Executive Summary
“Approvable” word from FDA represents a victory in tough antibiotic field.
You may also be interested in...
J&J/Basilea's Ceftobiprole Faces Another Setback
A Nov. 26 FDA complete response letter to Johnson & Johnson and Basilea Pharmaceutica for their antibiotic ceftobiprole cites deficiencies of study conduct and requests further clinical site audits
J&J/Basilea's Ceftobiprole Faces Another Setback
A Nov. 26 FDA complete response letter to Johnson & Johnson and Basilea Pharmaceutica for their antibiotic ceftobiprole cites deficiencies of study conduct and requests further clinical site audits
J&J/Basilea’s Ceftobiprole Gets Another Setback
FDA stops the investigational antibiotic’s six-month review clock for additional clinical site audits, data integrity review.